Project Retrovir (Pre-FRP → FRP Transition Draft)

Project Retrovir (Pre-FRP → FRP Transition Draft) Author: Mark Anthony Brewer, Brewtanius Ink LLC Date: September 2025 1. Introduction This document reframes earlier claims under the Foundational Recognition Protocol (FRP). Prior drafts presented speculative biomedical ideas as therapeutic candidates without meeting the evidentiary threshold of clinical trial registry data. This rewrite sets a new baseline: a timestamped, transparent exploratory note on KRAS-related oncology research, explicitly not a clinical claim. 2. Scope & Intent Scope: Capture and timestamp preliminary insights into viral-vector and retrotransposon-inspired approaches to disrupting KRAS oncogenic pathways. Intent: Provide a record of hypothesis-generation for future collaboration, critique, or lab investigation—not to claim a therapeutic candidate. Status: FRP-Compliant Draft — Not a therapy; not a preclinical trial. 3. Methodological Commitments To align with the Foundational Recognition Protocol, this document and its related artifacts are governed by a new set of commitments designed for transparency and verifiability. Temporal Integrity: This draft is cryptographically hashed (SHA-256) and timestamped with OpenTimestamps. This provides a public, immutable, and third-party verifiable record of when the work existed.1 Transparency: No therapeutic efficacy is implied; this is a hypothesis-only draft. All claims of "Project Retrovir" being "successful" or having discovered a drug candidate are formally withdrawn. Scientific Legibility: Terminology maps directly to established oncology frameworks: KRAS G12C mutations, retroviral insertion mechanisms, and targeted apoptosis pathways. Governance Clause: No biomedical claims will be advanced without public registry evidence (per FRP ethics standard), such as a formal submission to an official clinical trial registry. 4. Exploratory Contributions This section outlines a conceptual framework for a research program aimed at addressing the challenge of KRAS-mutated cancers, which are notoriously difficult to target directly with traditional small molecule inhibitors.3 Our hypothesis leverages gene therapy principles and the known mechanisms of retroviral vectors. Hypothesis: Retroviral or engineered retrotransposon-like agents may be designed to selectively disrupt mutated KRAS alleles while sparing wild-type sequences. Context: KRAS mutations are well-known drivers of colorectal, pancreatic, and lung cancers, promoting uncontrolled cell proliferation.4 While inhibitors for specific mutations like KRAS G12C exist, their application is limited to certain cancer types and can have significant side effects.3 Gene therapy, using vectors to deliver genetic material to cells, has shown promise in a variety of therapeutic strategies for cancer.6 Analogous Mechanisms: The use of viral vectors is a well-established method for delivering genetic material into cells.8 Retroviral vectors, in particular, are known for their ability to integrate their genetic material into the genome of the target cell, making them a potential candidate for targeting dividing cancer cells.8 The use of CRISPR/Cas9 and other transposon-based vectors provides a precedent for targeted genetic disruption. Speculative Pathways: Design a retroviral vector engineered to target oncogenic KRAS-expressing cells. Deliver a genetic payload that selectively disrupts mutated KRAS alleles. Trigger apoptosis in cancerous cells while minimizing off-target effects on healthy cells. Caveat: This is a conceptual sketch only. It is a hypothesis that has not been supported by any lab data, preclinical trials, or peer-reviewed evidence. 5. Limitations & Open Items No experimental data exist to support the efficacy of this approach. No preclinical safety studies or clinical trial registry entries have been created. There is no verified data on safety or efficacy. The work is a hypothesis and requires extensive interdisciplinary collaboration (molecular biology, oncology, virology) before it can even be considered for lab-based stages. 6. Next Steps (per FRP Phases) Phase 1: Maintain cryptographic timestamping and Zenodo DOI archival. Phase 2: Translate this note into a community-legible format (e.g., LaTeX) with clear disclaimers and a glossary of terms. Phase 3: Engage domain experts in oncology and virology for a formal critique. Phase 4: Only consider institutional submission if and when verifiable preclinical evidence exists. Phase 5: Pursue a formal clinical trial submission with a public registry only after all prior phases have been successfully completed. 7. Conclusion This paper is reframed from an overstated biomedical “solution” into an FRP-compliant exploratory hypothesis. It exists solely as a timestamped, auditable contribution to the knowledge commons, awaiting critique, validation, or dismissal by the biomedical community. Appendix A — Integrity Receipts SHA-256 digest: [pending] OpenTimestamps proof: [pending] Zenodo DOI: 10.5281/zenodo.17098311 Addendum — Clarification Under FRP This document exists solely as a timestamped exploratory hypothesis under the Foundational Recognition Protocol. No therapeutic candidate, preclinical trial, or safety/efficacy data is presented. All prior claims of biomedical “solutions” are formally withdrawn. This draft is a conceptual note only, awaiting critique, validation, or dismissal by the biomedical community. Any progression beyond hypothesis requires: Independent laboratory validation. Public clinical trial registration. Peer-reviewed publication in a recognized outlet. By publishing this addendum, Brewtanius Ink LLC affirms its compliance with FRP governance standards for biomedical claims.